Contact this trialFirst, we need to learn more about you.
Angiogenesis Inhibitor
Pembrolizumab + Lenvatinib for Advanced Cancers with Brain Metastases
Recruiting2 awardsPhase 2
Houston, Texas
This trial is testing a new combination of drugs to see if it is more effective than other treatments for patients with solid tumors and brain metastases. The primary endpoint is intracranial objective response rate, or the percentage of patients whose tumors shrink or disappear.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.